PURPOSE: To report long-term survival and toxicity outcomes with the use of high-dose intensity modulated radiation therapy (IMRT) to 86.4 Gy for patients with localized prostate cancer. METHODS AND MATERIALS: Between August 1997 and December 2008, 1002 patients were treated to a dose of 86.4 Gy using a 5-7 field IMRT technique. Patients were stratified by prognostic risk group based on National Comprehensive Cancer Network risk classification criteria. A total of 587 patients (59%) were treated with neoadjuvant and concurrent androgen deprivation therapy. The median follow-up for the entire cohort was 5.5 years (range, 1-14 years). RESULTS: For low-, intermediate-, and high-risk groups, 7-year biochemical relapse-free survival outcomes were 98.8%, 85.6%, and 67.9%, respectively (P<.001), and distant metastasis-free survival rates were 99.4%, 94.1%, and 82.0% (P<.001), respectively. On multivariate analysis, T stage (P<.001), Gleason score (P<.001), and >50% of initial biopsy positive core (P=.001) were predictive for distant mestastases. No prostate cancer-related deaths were observed in the low-risk group. The 7-year prostate cancer-specific mortality (PCSM) rates, using competing risk analysis for intermediate- and high-risk groups, were 3.3% and 8.1%, respectively (P=.008). On multivariate analysis, Gleason score (P=.004), percentage of biopsy core positivity (P=.003), and T-stage (P=.033) were predictive for PCSM. Actuarial 7-year grade 2 or higher late gastrointestinal and genitourinary toxicities were 4.4% and 21.1%, respectively. Late grade 3 gastrointestinal and genitourinary toxicity was experienced by 7 patients (0.7%) and 22 patients (2.2%), respectively. Of the 427 men with full potency at baseline, 317 men (74%) retained sexual function at time of last follow-up. CONCLUSIONS: This study represents the largest cohort of patients treated with high-dose radiation to 86.4 Gy, using IMRT for localized prostate cancer, with the longest follow-up to date. Our findings indicate that this treatment results in excellent clinical outcomes with acceptable toxicity.
PURPOSE: To report long-term survival and toxicity outcomes with the use of high-dose intensity modulated radiation therapy (IMRT) to 86.4 Gy for patients with localized prostate cancer. METHODS AND MATERIALS: Between August 1997 and December 2008, 1002 patients were treated to a dose of 86.4 Gy using a 5-7 field IMRT technique. Patients were stratified by prognostic risk group based on National Comprehensive Cancer Network risk classification criteria. A total of 587 patients (59%) were treated with neoadjuvant and concurrent androgen deprivation therapy. The median follow-up for the entire cohort was 5.5 years (range, 1-14 years). RESULTS: For low-, intermediate-, and high-risk groups, 7-year biochemical relapse-free survival outcomes were 98.8%, 85.6%, and 67.9%, respectively (P<.001), and distant metastasis-free survival rates were 99.4%, 94.1%, and 82.0% (P<.001), respectively. On multivariate analysis, T stage (P<.001), Gleason score (P<.001), and >50% of initial biopsy positive core (P=.001) were predictive for distant mestastases. No prostate cancer-related deaths were observed in the low-risk group. The 7-year prostate cancer-specific mortality (PCSM) rates, using competing risk analysis for intermediate- and high-risk groups, were 3.3% and 8.1%, respectively (P=.008). On multivariate analysis, Gleason score (P=.004), percentage of biopsy core positivity (P=.003), and T-stage (P=.033) were predictive for PCSM. Actuarial 7-year grade 2 or higher late gastrointestinal and genitourinary toxicities were 4.4% and 21.1%, respectively. Late grade 3 gastrointestinal and genitourinary toxicity was experienced by 7 patients (0.7%) and 22 patients (2.2%), respectively. Of the 427 men with full potency at baseline, 317 men (74%) retained sexual function at time of last follow-up. CONCLUSIONS: This study represents the largest cohort of patients treated with high-dose radiation to 86.4 Gy, using IMRT for localized prostate cancer, with the longest follow-up to date. Our findings indicate that this treatment results in excellent clinical outcomes with acceptable toxicity.
Authors: Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Niraj Pahlajani; Karen J Ruth; Mark K Buyyounouski; David Y T Chen; Eric M Horwitz; Gerald E Hanks; Robert A Price; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2011-07-15 Impact factor: 7.038
Authors: M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel Journal: J Urol Date: 2001-09 Impact factor: 7.450
Authors: M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel Journal: Radiother Oncol Date: 2000-06 Impact factor: 6.280
Authors: Véronique Beckendorf; Stéphane Guérif; Elisabeth Le Prisé; Jean Marc Cosset; Olivier Lefloch; Bruno Chauvet; Naji Salem; Olivier Chapet; Sylvain Bourdin; Jean Marc Bachaud; Philippe Maingon; Jean-L Eon Lagrange; Luc Malissard; Jean-Marc Simon; Pascal Pommier; Men H Hay; Bernard Dubray; Elisabeth Luporsi; Pierre Bey Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Jeff M Michalski; Kyounghwa Bae; Mack Roach; Arnold M Markoe; Howard M Sandler; Janice Ryu; Matthew B Parliament; William Straube; Richard K Valicenti; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038
Authors: Mitchell S Anscher; Michael G Chang; Drew Moghanaki; Mihaela Rosu; Ross B Mikkelsen; Diane Holdford; Vicki Skinner; Baruch M Grob; Arun Sanyal; Aiping Wang; Nitai D Mukhopadhyay Journal: Am J Clin Oncol Date: 2018-06 Impact factor: 2.339
Authors: Marigdalia K Ramirez-Fort; Marc J Rogers; Roberto Santiago; Sean S Mahase; Melissa Mendez; Yi Zheng; Xiang Kong; James A Kashanian; M Junaid Niaz; Shearwood McClelland; Xiaodong Wu; Neil H Bander; Peter Schlegel; John P Mulhall; Christopher S Lange Journal: Rep Pract Oncol Radiother Date: 2020-03-19
Authors: Tomasz Barelkowski; Peter Wust; David Kaul; Sebastian Zschaeck; Waldemar Wlodarczyk; Volker Budach; Pirus Ghadjar; Marcus Beck Journal: Strahlenther Onkol Date: 2019-12-23 Impact factor: 3.621
Authors: Per Munck af Rosenschöld; Neil B Desai; Jung Hun Oh; Aditya Apte; Margie Hunt; Abraham Kalikstein; James Mechalakos; Laura Happersett; Joseph O Deasy; Michael J Zelefsky Journal: Radiother Oncol Date: 2014-02-20 Impact factor: 6.280
Authors: Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu Journal: J Clin Invest Date: 2013-09-16 Impact factor: 14.808
Authors: Daniel E Spratt; Hebert A Vargas; Zachary S Zumsteg; Jennifer S Golia Pernicka; Joseph R Osborne; Xin Pei; Michael J Zelefsky Journal: Eur Urol Date: 2016-08-11 Impact factor: 20.096
Authors: Pirus Ghadjar; Andrew Jackson; Daniel E Spratt; Jung Hun Oh; Per Munck af Rosenschöld; Marisa Kollmeier; Ellen Yorke; Margie Hunt; Joseph O Deasy; Michael J Zelefsky Journal: Eur Urol Date: 2013-02-14 Impact factor: 20.096